Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma: A nationwide cancer registry study

Cutaneous squamous cell carcinoma (cSCC) represents the most serious form of keratinocyte cancers because of its metastatic potential. Studies on nationwide incidence and disease-specific survival rates of metastatic cSCC (mcSCC) are lacking. To investigate the cumulative incidence and disease-speci...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2022-02, Vol.86 (2), p.331-338
Main Authors: Tokez, Selin, Wakkee, Marlies, Kan, Wilner, Venables, Zoe C., Mooyaart, Antien L., Louwman, Marieke, Nijsten, Tamar, Hollestein, Loes M.
Format: Article
Language:English
Subjects:
cancer registry
Carcinoma, Squamous Cell - epidemiology
Carcinoma, Squamous Cell - pathology
cutaneous squamous cell carcinoma
epidemiology
hematologic malignancy
Humans
Incidence
keratinocyte carcinoma
Male
metastasis
organ transplantation
Registries
Risk Factors
Skin Neoplasms - epidemiology
Skin Neoplasms - pathology
survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cutaneous squamous cell carcinoma (cSCC) represents the most serious form of keratinocyte cancers because of its metastatic potential. Studies on nationwide incidence and disease-specific survival rates of metastatic cSCC (mcSCC) are lacking. To investigate the cumulative incidence and disease-specific survival of patients with mcSCC in the Dutch population and assess patient-based risk factors. We conducted a nationwide cancer registry study including all patients with the first cSCC in 2007 or 2008, using data from the Netherlands Cancer Registry, the nationwide network and registry of histopathology and cytopathology, and Statistics Netherlands. Cumulative incidence and Kaplan-Meier curves were calculated, and time-dependent Cox proportional hazards regression analyses were used. Of the 11,137 patients, metastases developed in 1.9% (n = 217). The median time to metastasis was 1.5 years (interquartile range 0.6-3.8 years). The risk factors were age (adjusted hazard ratio [aHR] 1.03, 95% CI 1.02-1.05), male sex (aHR 1.7, 95% CI 1.3-2.3), and immunosuppression (aHR [organ transplant recipient] 5.0, 95% CI 2.5-10.0; aHR [hematologic malignancy] 2.7, 95% CI 1.6-4.6). The 5-year disease-specific survival for patients with mcSCC was 79.1%. Only histopathologically confirmed mcSCCs were included. About 2% of cSCCs metastasize, with higher risk for men, increasing age, and immunocompromised patients. Disease-specific survival for patients with mcSCC is high.
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2021.09.067